Clinical Trial Update: A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of Glembatumumab Vedotin as monotherapy or with immunotherapies in advanced melanoma was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2019-09-06